Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
PMD Law Amendment Bill Clears Lower House Health Panel
The Lower House health committee of the Diet passed a bill to amend the Pharmaceuticals and Medical Devices (PMD) Law on November 13 after a tumultuous six-hour session, where opposition parties grilled the government on issues unrelated to the legislation.…
To read the full story
Related Article
- Japan Sets 1st Rollout of Amended PMD Law for Sept. 1
March 9, 2020
- Amended PMD Law Promulgated, 3-Step Enforcement to Begin Next Year
December 5, 2019
- Amended PMD Law Set for 3-Step Enforcement, 1st Execution Eyed Next Autumn
November 28, 2019
- Japan Enacts Amended Pharmaceuticals and Medical Devices Law
November 27, 2019
- Upper House Panel Discusses PMD Law Amendment Bill, Another Session Set for Nov. 26
November 22, 2019
- Lower House OKs PMD Law Amendment Bill
November 15, 2019
- Substantive Diet Discussions Get Underway for PMD Law Amendment
November 7, 2019
- Discussions on PMD Law Amendment Bill Start in Extraordinary Diet
October 24, 2019
- Health Minister Keen on Passage of PMD Law Amendment in Extra Diet Session
October 8, 2019
- As Curtain Rises on Diet, MHLW Aims to Get Amended PMD Bill Enacted in Early November
October 7, 2019
- MHLW Pharma Bureau Chief Keen on Early Enactment of PMD Amendment Bill
August 5, 2019
REGULATORY
- Japan Ranks 9th Among 10 in AI Analysis of EFPIA Pharma Strategy Report
March 27, 2026
- MHLW Says Trial Recruitment Info Not Deemed Advertising Under PMD Act
March 27, 2026
- AMED Warns Projects without Japan Return May Miss Startup Funding
March 26, 2026
- Japan Cabinet Approves National MCM Strategy to Boost Pandemic Response
March 25, 2026
- Pharma Urges Govt Support as Iran War Shows Early Impact on Supply Chains
March 25, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…